Reduced duration and dosage of venetoclax is efficient in newly diagnosed patients with acute myeloid leukemia-Reference-Cited by-同舟云学术

Reduced duration and dosage of venetoclax is efficient in newly diagnosed patients with acute myeloid leukemia

Published:2023-12-14 Issue:1 Volume:29 Page:
ISSN:1607-8454
Container-title:Hematology
language:en
Short-container-title:Hematology

Author:

Cui Jingying¹²,Chen Xuexing²,Li Chunfang²,Yan Qiong²,Yuan Guolin²

Affiliation:

1. School of Medicine, Wuhan University of Science and Technology, Wuhan, People’s Republic of China

2. Department of Hematology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, People’s Republic of China

Publisher

Informa UK Limited

Subject

Hematology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/16078454.2023.2293512

Reference24 articles.

1. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

2. Venetoclax: A New Partner in the Novel Treatment Era for Acute Myeloid Leukemia and Myelodysplastic Syndrome

3. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

4. A real-world study of infectious complications of venetoclax combined with decitabine or azacitidine in adult acute myeloid leukemia

5. Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Less is more: An analysis of venetoclax and hypomethylating agent post-induction treatment modifications in AML;Leukemia Research;2024-08

2. Ven the dose matters: Venetoclax dosing in the frontline treatment of AML;Blood Reviews;2024-08

3. Prescription patterns of venetoclax in acute myeloid leukemia;Hematological Oncology;2024-07

4. Venetoclax and hypomethylating agents in octogenarians and nonagenarians with acute myeloid leukemia;Blood Neoplasia;2024-06